^
Association details:
| Biomarker: | CD79B mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | JNJ-4681 (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DISCOVERY AND PRECLINICAL PROPERTIES OF JNJ-64264681, A POTENT AND SELECTIVE COVALENT BTK INHIBITOR FOR THE TREATMENT OF B CELL MALIGNANCIES
Published date:
05/12/2021
Excerpt:
Treatment with JNJ-64264681 led to potent in vivo BTK occupancy, inhibition of specific cytokines and tumor growth inhibition in a CD79b-mutant ABC-DLBCL xenograft model.
